NCT04489264招募中不适用
A Prospective Study of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Peking University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年11月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 & PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with confirmed pathological diagnosis of aggressive PTCL
- •Age 18-65 years old
- •Achieving CR or PR after first-line therapy
排除标准
- •Subtypes with a more indolent course, including precursor T/natural killer neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, Sézary syndrome, and primary cutaneous CD30-positive disorders.
研究组 & 干预措施
ASCT group
patients who achieved CR or PR after 6-8 cycles first-line therapy receive ASCT as consolidation therapy
干预措施: Transplant, Autologous (Drug)
结局指标
主要结局
PFS
时间窗: 2-year PFS
次要结局
未报告次要终点
研究者
Jun Zhu
Party secretary of Cancer Hospital of Peking University, Director of Internal Medicine
Peking University
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström MacroglobulinemiaWaldenström MacroglobulinemiaNCT02844361Institute of Hematology & Blood Diseases Hospital, China70
已完成
1 期
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Childhood Hodgkin LymphomaRecurrent Childhood Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin LymphomaProlymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Childhood Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRefractory Small Lymphocytic LymphomaT-Cell Chronic Lymphocytic LeukemiaT-Cell Prolymphocytic LeukemiaNCT00005803Fred Hutchinson Cancer Center76
已完成
1 期
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic MalignanciesLeukemiaMultiple MyelomaNCT00477035Sally Arai22
已完成
不适用
EBMT ADWP Prospective Non Interventional Study : AutoHSCT in SSc PatientsAutoimmune DiseasesNCT02516124European Society for Blood and Marrow Transplantation82
终止
2 期
Autologous and Allogenic Transplantation With Campath-1H for T-Cell LymphomaLymphomaNCT00505921M.D. Anderson Cancer Center27